Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

People In Brief

This article was originally published in The Tan Sheet

Executive Summary

McDonald succeeds Lafley as P&G chairman: A.G. Lafley hands over the reins as Procter & Gamble chairman to Bob McDonald on Jan. 1, 2010 - almost two months before he will retire. The move is part of a phased-in leadership transition that began in June when Lafley passed the president and CEO baton to McDonald (1"The Tan Sheet" June 15, 2009). In the 10 years Lafley was president and CEO, Cincinnati-based P&G doubled its sales and grew its portfolio of billion-dollar brands from 10 to 22, according to a Dec. 8 release. ... WellPoint's Braly joins board: In a same-day release, P&G says it appointed WellPoint President and CEO Angela F. Braly to its board effective immediately. WellPoint, a health benefits provider with 34 million members, has initiated coverage for OTC products in some areas (2"The Tan Sheet" May 26, 2008)

You may also be interested in...



Chastened By Cold-FX Flop, Afexa Plots U.S. Return Via Botanical Drug Path

Canadian firm Afexa Life Sciences turns its sights southward again, hoping a strong commitment to clinical research will help its flagship Cold-FX product catch on in the U.S.

Chastened By Cold-FX Flop, Afexa Plots U.S. Return Via Botanical Drug Path

Canadian firm Afexa Life Sciences turns its sights southward again, hoping a strong commitment to clinical research will help its flagship Cold-FX product catch on in the U.S.

Chastened By Cold-FX Flop, Afexa Plots U.S. Return Via Botanical Drug Path

Canadian firm Afexa Life Sciences turns its sights southward again, hoping a strong commitment to clinical research will help its flagship Cold-FX product catch on in the U.S.

Related Content

Latest News
See All
UsernamePublicRestriction

Register

PS103622

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel